Emerging drugs for the treatment of Myelofibrosis.

Expert Opinion on Emerging Drugs
Aditya Shreenivas, John Mascarenhas

Abstract

Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN). It can be sub-categorized into primary myelofibrosis, post polycythemia vera myelofibrosis and post essential thrombocythemia myelofibrosis. MF is a life-threatening hematologic malignancy characterized by dysregulation of the Janus associated kinase (JAK)/signal transducer and activator of transcription (STAT) signaling network and a heightened inflammatory state. Areas covered: We cover the pathogenesis, clinical features, new prognostic models, current treatment of MF and discuss agents in development. We also cover market review and health care costs associated with some of these therapies. Expert opinion: There are many ongoing clinical trials evaluating novel therapeutic approaches, including selective JAK inhibitors, histone deacetylase/DNA methyltransferase inhibitors, PI3K-inhibitors, Hedgehog/mammalian target of rapamycin (MTOR) inhibitors, anti-fibrotic agents, immunomodulators, monoclonal antibodies and immune checkpoint inhibitors. Ruxolitinib, a potent oral JAK1/JAK2 inhibitor remains the only Food and Drug Administration (FDA)-approved medicinal therapy for the treatment of MF. Unmet needs include alleviation of limiting t...Continue Reading

References

Apr 27, 2000·The New England Journal of Medicine·A Tefferi
Jul 13, 2004·Mayo Clinic Proceedings·Ruben A MesaAyalew Tefferi
Apr 29, 2005·The New England Journal of Medicine·Robert KralovicsRadek C Skoda
Apr 13, 2006·Blood·Ayalew TefferiHagop M Kantarjian
Oct 26, 2006·Nature Reviews. Immunology·Gavin P DunnRobert D Schreiber
May 15, 2007·Biochemical Pharmacology·Keith B Glaser
Dec 26, 2007·The Journal of Biological Chemistry·Xiaohui LuHarvey F Lodish
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alfonso Quintás-CardamaSrdan Verstovsek
Jul 7, 2010·Drug News & Perspectives·Jeremy S Duffield, Mark L Lupher
Sep 17, 2010·The New England Journal of Medicine·Srdan VerstovsekAyalew Tefferi
Nov 6, 2010·Leukemia·K H BegnaA Tefferi
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naseema GangatAyalew Tefferi
Feb 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ayalew TefferiAnimesh Pardanani
May 31, 2011·Blood·Elias JabbourSrdan Verstovsek
Mar 2, 2012·The New England Journal of Medicine·Claire HarrisonGiovanni Barosi
Mar 2, 2012·The New England Journal of Medicine·Srdan VerstovsekHagop M Kantarjian
Apr 6, 2012·Leukemia Research·Alfonso Quintás-CardamaSrdan Verstovsek
May 1, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Albert DeisserothRichard Pazdur
Jul 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francisco CervantesArturo Pereira
Oct 17, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robyn M EmanuelRuben A Mesa
May 21, 2013·Leukemia & Lymphoma·John MascarenhasRonald Hoffman
Jun 19, 2013·Leukemia & Lymphoma·Jyotsna MehtaRuben Mesa
Oct 5, 2013·Haematologica·John O MascarenhasRonald Hoffman
Dec 12, 2013·The New England Journal of Medicine·Thorsten KlampflRobert Kralovics
Dec 12, 2013·The New England Journal of Medicine·J NangaliaA R Green

❮ Previous
Next ❯

Citations

Oct 17, 2018·Expert Review of Hematology·Eran ZimranMarina Kremyanskaya
May 29, 2021·RSC Medicinal Chemistry·Alexandria M Chan, Steven Fletcher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Related Papers

Expert Opinion on Emerging Drugs
Ehab Atallah, Srdan Verstovsek
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Hun Ju LeeFarhad Ravandi
Hematology/oncology Clinics of North America
Warren FiskusKapil N Bhalla
© 2022 Meta ULC. All rights reserved